BAQSIMI (GLUCAGON) POWDER [AMPHASTAR PHARMACEUTICALS, INC.]
Aug 11, 2025
- Route
- intranasal
- Form
- Not reported
- Holder
- Amphastar Pharmaceuticals, Inc.
- Scope
- Direct label match
Product·link reviewed
Glucagon
ATLPD0000051
Product-level evidence profile for identity and molecular form, PK exposure, clinical context, safety context, label material, and reproducible data access.
- ADMETatlas IDATLPD0000051
- Peptide-link statusDefined molecular entity
- Linked peptides1
- Product routesubcutaneous
- PK summaries14
- Trial references41
- Matched label records23
- Curated label context1
- Regulatory-label PK13
Product evidence profile
Product identity and molecular form, PK exposure evidence, safety context, clinical and label context, interpretation boundaries, and reproducibility exits available for this product.
Profile overview
5 of 6 profile areas have current evidence, product context, or reviewed identity linkage.
AvailableNo current evidence
Linked peptides
1
Defined molecular entity
PK summaries
14
15 cited source records
Product-linked records
75
42 context · 33 identity support
Product-label scope
23 matches
23 matched records · 1 curated contexts · 13 regulatory-label PK measurements
Profile areas
A compact route into product identity and molecular form, exposure evidence, context lanes, interpretation boundaries, and reproducible access.
Available
Molecular identity & structure
What is this product, which peptide does it map to, and what is its structure?
ATLPD0000051
subcutaneous
Empty
Pharmacology
What is the drug used for and how does it act?
—
not curated
Available
Pharmacokinetics
Are there curated exposure / PK summaries or cited observations?
14
14 summaries · 15 measurements
Available
Safety & immunogenicity
What safety, postmarketing, and immune-recognition signals surround the product?
1
AE, immune & nonclinical context
Available
Clinical & regulatory
What trial and product-label context is attached to this product?
41 trials
41 trials · 1 curated label contexts · 23 matched label records · 13 label-derived PK measurements
Available
Provenance, scope & access
How is the evidence scoped, traced, cited, and reopened?
Trace
scope · lineage · access
One. Molecular identity & structure
What the product is, how its complete molecular form is defined, and which chemical or structural representations support that identity.
Identity
Scientific product record
Glucagon
ATLPD0000051This product identity anchors product-level label, trial, postmarketing, and PK context. Route, form, and holder fields are shown when they are normalized from product or label references, not inferred from the product name.
Peptide link
Defined molecular entity
1 linked peptide
Product context
42 curated anchors
1 label context · 41 trial
Identity fields
- Product name
- Glucagon
- ADMETatlas product ID
- ATLPD0000051
- Aliases / marketed names
- BaqsimiGlucaGenGlucaGen HypoKitGlucag0nGlucagon Ampoule 666 1mgGvoke HypoPen 0.5 mg Auto-InjectorGvoke HypoPen 1 mg Auto-InjectorGvoke KitGvoke Kit VialGvoke PFS 0.5 mg Pre-filled SyringeGvoke PFS 1 mg Pre-filled SyringeOgluo
- Route
- subcutaneous
Identity anchors
These anchors support product-level lookup and context attachment. They are identity evidence, not ADMET endpoint measurements.
Peptide identity
Defined molecular entity
1 linked peptide
Matched label records
23
Label/formulation matches; routes remain scoped to the source records.
Curated label context
1
Structured product-label context available for this identity.
Regulatory-label PK
13
Human PK measurements extracted from official product labeling.
Trial references
41
Clinical-trial context attached through product identity.
Name-normalization matches
not available
Review status: —.
Drug classification (ATC)
- H04AA01 · glucagon
ATC classification © WHO Collaborating Centre for Drug Statistics Methodology; used unmodified for non-commercial research.
Label formulation evidence
Matched label records
23
direct and combination-label matches
Routes
intramuscular; intranasal; intravenous; oral; subcutaneous
source-stated in these records, not a product-wide route
Forms
Injection, powder, lyophilized, for solution; Injection, solution; Kit
multiple source-stated forms
Veterinary labels
0
none explicitly identified
GLUCAG0N (GLUCAGON KIT) KIT [HF ACQUISITION CO LLC, DBA HEALTHFIRST]
Dec 12, 2022
- Route
- intravenous; subcutaneous; intramuscular
- Form
- Kit
- Holder
- Hf Acquisition Co LLC, Dba Healthfirst
- Scope
- Direct label match
GLUCAGON (GLUCAGON) KIT [FRESENIUS KABI USA, LLC]
Apr 02, 2025
- Route
- intramuscular; intravenous
- Form
- Kit
- Holder
- Fresenius Kabi USA, LLC
- Scope
- Direct label match
GLUCAGON (GLUCAGON) KIT [LUPIN PHARMACEUTICALS, INC.]
Aug 07, 2025
- Route
- intramuscular; intravenous; subcutaneous
- Form
- Kit
- Holder
- Lupin Pharmaceuticals, Inc.
- Scope
- Direct label match
GLUCAGON 1555 (GLUCAGON) LIQUID [PROFESSIONAL COMPLEMENTARY HEALTH FORMULAS]
Jan 12, 2026
- Route
- oral
- Form
- Not reported
- Holder
- Professional Complementary Health Formulas
- Scope
- Direct label match
GLUCAGON INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION GLUCAGON KIT [FRESENIUS KABI USA, LLC]
Apr 20, 2022
- Route
- intravenous; intramuscular
- Form
- Injection, powder, lyophilized, for solution
- Holder
- Fresenius Kabi USA, LLC
- Scope
- Direct label match
GLUCAGON KIT [A-S MEDICATION SOLUTIONS]
Jul 24, 2023
- Route
- intravenous; intramuscular; subcutaneous
- Form
- Kit
- Holder
- A-S Medication Solutions
- Scope
- Direct label match
GLUCAGON KIT [CIPLA USA INC.]
Nov 17, 2025
- Route
- subcutaneous; intramuscular; intravenous
- Form
- Kit
- Holder
- Cipla USA Inc.
- Scope
- Direct label match
| Label / formulation | Route | Form | Holder | Context | Reference |
|---|---|---|---|---|---|
BAQSIMI (GLUCAGON) POWDER [AMPHASTAR PHARMACEUTICALS, INC.] Aug 11, 2025 | intranasal | — | Amphastar Pharmaceuticals, Inc. | Direct label match | DailyMed record |
GLUCAG0N (GLUCAGON KIT) KIT [HF ACQUISITION CO LLC, DBA HEALTHFIRST] Dec 12, 2022 | intravenous; subcutaneous; intramuscular | Kit | Hf Acquisition Co LLC, Dba Healthfirst | Direct label match | DailyMed record |
GLUCAGON (GLUCAGON) KIT [FRESENIUS KABI USA, LLC] Apr 02, 2025 | intramuscular; intravenous | Kit | Fresenius Kabi USA, LLC | Direct label match | DailyMed record |
GLUCAGON (GLUCAGON) KIT [LUPIN PHARMACEUTICALS, INC.] Aug 07, 2025 | intramuscular; intravenous; subcutaneous | Kit | Lupin Pharmaceuticals, Inc. | Direct label match | DailyMed record |
GLUCAGON 1555 (GLUCAGON) LIQUID [PROFESSIONAL COMPLEMENTARY HEALTH FORMULAS] Jan 12, 2026 | oral | — | Professional Complementary Health Formulas | Direct label match | DailyMed record |
GLUCAGON INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION GLUCAGON KIT [FRESENIUS KABI USA, LLC] Apr 20, 2022 | intravenous; intramuscular | Injection, powder, lyophilized, for solution | Fresenius Kabi USA, LLC | Direct label match | DailyMed record |
GLUCAGON KIT [A-S MEDICATION SOLUTIONS] Jul 24, 2023 | intravenous; intramuscular; subcutaneous | Kit | A-S Medication Solutions | Direct label match | DailyMed record |
GLUCAGON KIT [CIPLA USA INC.] Nov 17, 2025 | subcutaneous; intramuscular; intravenous | Kit | Cipla USA Inc. | Direct label match | DailyMed record |
Record-set scope (23 matched labels)
The table shows 8 representative records across route, formulation, direct/combination context, and identified veterinary status. The complete 23-record set remains available in the structured product profile.
Linked peptide identity
Link decision
Defined molecular entity
Product-level label, safety, trial, and PK context may be read beside the linked peptide identity. Endpoint truth still remains controlled by endpoint-specific evidence and compatibility rules.
Context link
Reviewed
context interpretation allowed
Linked identities
1
canonical peptide identities
Reference traces
8
source-matching records
Reference peptide identity
The public link view emphasizes sequence, identity role, reference support, and interpretation boundary rather than non-public peptide identifiers.
- Identity role
- Reference identity
- Sequence
- HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
- Residue length
- 29 residues
- Reference support
- 0 supporting references
Linked identity set
Multiple linked identities can reflect reviewed source-sequence differences, variant entries, or precursor-like entries. Use the reference identity as the main product-context link.
Reference identity
Canonical sequence
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
29 residues · 0 supporting references
Source matching trace8 records
| Identity match | Reference | Link review |
|---|---|---|
| Product context only | Evidence context | Source match only |
| Product context only | Evidence context | Source match only |
| Product context only | Evidence context | Source match only |
| Product context only | Evidence context | Source match only |
| Product context only | Evidence context | Source match only |
| Product context only | Evidence context | Source match only |
| Product context only | Evidence context | Source match only |
| Product context only | Evidence context | Source match only |
Interpretation boundary
The link supports product-context interpretation beside a peptide identity. It is not a measured endpoint, and it does not promote label, safety, or trial context into peptide-level endpoint truth by itself.
Structure reference·
3D coordinates·Sequence matchexperimental
Sequence match·reference selected·identity 100.0%·confidence experimental
Structure shown for the reviewed peptide identity linked to this product (ATLPC0002714). Experimental / model 3D coordinate references; use the reference selector to compare.
A 2D graph describes connectivity, not conformation; a 3D reference describes one coordinate model, not the full ensemble.
Open linked peptide · ATLPC0002714Two. Pharmacology: indication & mechanism
What the drug is used for and how it acts, based on curated therapeutic indications and mechanism-of-action evidence for the product identity.
Indication & mechanism of action
No curated mechanism-of-action or indication evidence is attached to this product in the current release.
Three. Pharmacokinetics & exposure
Traceable exposure and PK properties across product labels, literature, and nonclinical evidence.
Pharmacokinetics & exposure
Whole-product PK evidence
Exposure values for the complete product as tested.
0 summaries · 1 measurements
PK evidence
Traceable exposure properties
Human product-label values are shown first, followed by additional source-backed evidence.
PK properties
6
14 grouped summaries
Human label PK
13
13 cited measurements
Additional source values
1
1 source-reported value outside grouped summaries
Measurement trace
15
source observations
Curated PK property coverage
1
AUC
1
Bioavailability
1
Clearance
4
Cmax
4
Tmax
3
Vd
Human label PK
Human exposure properties reported in official product labeling.
AUC
Regulatory product label
3,455 pg*min/mL
human · subcutaneous
1 trace
Clearance
Regulatory product label
13.5 mL/min/kg
human
1 trace
Cmax
Regulatory product label
2,481 pg/mL
human · subcutaneous
1 trace
Cmax
Regulatory product label
6,130 pg/mL
human · plasma
1 trace
Cmax
Regulatory product label
6.9 ng/mL
human · intramuscular · plasma
1 trace
Cmax
Regulatory product label
7.9 ng/mL
human · subcutaneous · plasma
1 trace
Tmax
Regulatory product label
≈1,200 seconds
human · subcutaneous · plasma
1 trace
Tmax
Regulatory product label
≈780 seconds
human · intramuscular · plasma
1 trace
Tmax
Regulatory product label
≈900 seconds
human · plasma
1 trace
Tmax
Regulatory product label
3,000 seconds
human · subcutaneous
1 trace
Vd
Regulatory product label
≈885 L
human
1 trace
Vd
Regulatory product label
0.25 L/kg
human · subcutaneous · serum
1 trace
Vd
Regulatory product label
137-2,425 L
human · subcutaneous
1 trace
Additional PK evidence
Other source-backed PK properties across labels, literature, and nonclinical studies.
Bioavailability
Supporting evidence
16 %
human · intranasal · serum
1 trace
Additional source-reported values
Direct source values extend the product's PK endpoint profile.
PPB
Supporting evidence
No binding
multiple · plasma_protein
source value
Cited measurement trace15 observations
1-10 / 15
AUC
3,455 pg*min/mL
- Context
- human · subcutaneous
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: 12.3 Pharmacokinetics Absorption Subcutaneous injection of 1 mg GVOKE in adult type 1 diabetes mellitus patients resulted in a mean glucagon C max of 2481.3 pg/mL, t max of 50 minutes and AUC 0‑240min of 3454.6 pg*min...
Bioavailability
16 %
- Context
- human · intranasal · serum
- Measured material
- Reported analyte
- Evidence role
- Curated comparable measurement
- Reference
- Reference
Reported statement: The relative bioavailability of NG compared with INJ was 16%.
Clearance
13.5 mL/min/kg
- Context
- human
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: Elimination The mean clearance was 13.5 mL/min/kg.
Cmax
6.9 ng/mL
- Context
- human · intramuscular · plasma
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte...
Cmax
7.9 ng/mL
- Context
- human · subcutaneous · plasma
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte...
Cmax
6,130 pg/mL
- Context
- human · plasma
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: 12.3 Pharmacokinetics Absorption Glucagon absorption via the intranasal route, achieved mean peak plasma levels of 6130 pg/mL at around 15 minutes.
Cmax
2,481 pg/mL
- Context
- human · subcutaneous
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: 12.3 Pharmacokinetics Absorption Subcutaneous injection of 1 mg GVOKE in adult type 1 diabetes mellitus patients resulted in a mean glucagon C max of 2481.3 pg/mL, t max of 50 minutes and AUC 0‑240min of 3454.6 pg*min...
PPB
No binding
- Context
- multiple · plasma_protein
- Measured material
- Whole product
- Evidence role
- Source-reported observation
- Reference
- Source record
Reported statement: Reference entry retained for traceability.
Tmax
≈780 seconds
- Context
- human · intramuscular · plasma
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte...
Tmax
≈1,200 seconds
- Context
- human · subcutaneous · plasma
- Measured material
- Reported analyte
- Evidence role
- Source-reported product-label value
- Reference
- Reference
Reported statement: 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte...
| PK property | Value | Context | Reference | Measured material | Evidence role | Reported statement |
|---|---|---|---|---|---|---|
| AUC | 3,455 pg*min/mL | human · subcutaneous | Reference | Reported analyte | Source-reported product-label value | 12.3 Pharmacokinetics Absorption Subcutaneous injection of 1 mg GVOKE in adult type 1 diabetes mellitus patients resulted in a mean glucagon C max of 2481.3 pg/mL, t max of 50 minutes and AUC 0‑240min of 3454.6 pg*min... |
| Bioavailability | 16 % | human · intranasal · serum | Reference | Reported analyte | Curated comparable measurement | The relative bioavailability of NG compared with INJ was 16%. |
| Clearance | 13.5 mL/min/kg | human | Reference | Reported analyte | Source-reported product-label value | Elimination The mean clearance was 13.5 mL/min/kg. |
| Cmax | 6.9 ng/mL | human · intramuscular · plasma | Reference | Reported analyte | Source-reported product-label value | 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte... |
| Cmax | 7.9 ng/mL | human · subcutaneous · plasma | Reference | Reported analyte | Source-reported product-label value | 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte... |
| Cmax | 6,130 pg/mL | human · plasma | Reference | Reported analyte | Source-reported product-label value | 12.3 Pharmacokinetics Absorption Glucagon absorption via the intranasal route, achieved mean peak plasma levels of 6130 pg/mL at around 15 minutes. |
| Cmax | 2,481 pg/mL | human · subcutaneous | Reference | Reported analyte | Source-reported product-label value | 12.3 Pharmacokinetics Absorption Subcutaneous injection of 1 mg GVOKE in adult type 1 diabetes mellitus patients resulted in a mean glucagon C max of 2481.3 pg/mL, t max of 50 minutes and AUC 0‑240min of 3454.6 pg*min... |
| PPB | No binding | multiple · plasma_protein | Source record | Whole product | Source-reported observation | Reference entry retained for traceability. |
| Tmax | ≈780 seconds | human · intramuscular · plasma | Reference | Reported analyte | Source-reported product-label value | 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte... |
| Tmax | ≈1,200 seconds | human · subcutaneous · plasma | Reference | Reported analyte | Source-reported product-label value | 12.3 Pharmacokinetics Absorption Glucagon injected through the intramuscular route achieved mean peak plasma levels of 6.9 ng/mL at approximately 13 minutes after dosing; and 7.9 ng/mL at approximately 20 minutes afte... |
1–10 / 15
How PK values are grouped
Summaries keep species, unit, route, dose, matrix, population, and source context separate. Whole-product values stay attached to the complete product.
Four. Safety & immunogenicity
Regulatory safety warnings, postmarketing and nonclinical safety context, and immune-recognition context. These describe available signals, not incidence rates or causality.
Safety & immunogenicity
Postmarketing safety
0
report entries
Immune recognition
1
assay entries
Nonclinical safety
0
context entries
Product context landscape shows 1 of 3 lanes with current signal support for this product.
LaneCountCurrent signalBoundary
Postmarketing safety
No report context attached
0
report entries
No postmarketing safety report context attached.
Serious: 0 (0%)Reactions: 0Countries: 0
Spontaneous reports are safety-surveillance context only. They do not establish incidence, comparative risk, or causality.External search
Immune recognition
Immune-assay context attached
1
assay entries
Hla I Ligand Fragment Observed accounts for 1 retained assay entry.
Positive: 0Negative: 0MHC classes: 1
Immune-assay entries show epitope or MHC recognition assay context. They are not clinical immunogenicity incidence.Context entries
Nonclinical safety
No nonclinical safety context attached
0
context entries
No nonclinical safety context attached.
Label refs: 0Reviewed refs: 0Species: 0
Nonclinical safety entries retain animal, toxicology, or label context and are not normalized human safety endpoints.Context entries
The source-level context signal index is deferred from the initial product profile. Use the context-lane links above or the structured product profile below to inspect all 42 retained context signal entries.
Interpretation boundary Product-context signals are retained for interpretation and traceability. They are not incidence rates, causal safety findings, or normalized peptide endpoint measurements.
Five. Clinical & regulatory evidence
Clinical-trial context and structured product-label references attached by product identity.
Clinical & regulatory evidence
Human study context
41
trial signals
Regulatory label
1
label contexts
Product context landscape shows 2 of 2 lanes with current signal support for this product.
LaneCountCurrent signalBoundary
Human study context
Study registry context attached
41
trial signals
NCT06660134: Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF
Strong NCTs: 15Exact match: 10Has results: 14
Study registry references provide trial context. Phase, status, and posted-results metadata are not endpoint evidence by themselves.Registry search
Regulatory label
Supporting label context
1
label contexts
No structured label reference attached.
Label refs: 1Reviewed AE: 0Immunogenicity: 0
Product-label entries are regulatory product-label context unless an entry is separately promoted by endpoint-specific policy.Label search
The source-level context signal index is deferred from the initial product profile. Use the context-lane links above or the structured product profile below to inspect all 42 retained context signal entries.
Interpretation boundary Product-context signals are retained for interpretation and traceability. They are not incidence rates, causal safety findings, or normalized peptide endpoint measurements.
Six. Provenance, scope & access
How to read, trace, cite, and reopen this profile: evidence scope, reference lineage, and reproducible data access.
Evidence scope
How to read this profile
Evidence roles stay separate before interpretation
Endpoint summaries, product-context lanes, identity links, and source references answer different questions. This boundary keeps the page useful without converting context into stronger claims than the current review layer supports.
Endpoint comparison
Traceable within endpoint context
Compare PK results only when endpoint and experimental context are compatible.
Product-context reading
Context available, not endpoint truth
Label, trial, safety, immune, and nonclinical records remain contextual unless separately extracted as an endpoint.
Context propagation
Allowed for product-context reading
Defined molecular entity
Detailed interpretation and provenance guidance
Scientific interpretation details
SurfaceEvidence roleSupportsDoes not supportRelated evidence
Curated endpoint evidence
Evidence role
Comparable measurement layer
Supports
Endpoint-level interpretation when context fields match.
Does not support
Pooled product parameters across mismatched species, units, route, dose, matrix, population, or source context.
Product-context signals
Evidence role
Clinical, label, safety, immune, and nonclinical context
Supports
Reading the product's evidence surroundings and source-backed context lanes.
Does not support
Incidence rates, causality claims, product safety ranking, or normalized ADMET endpoint values.
Peptide identity
Evidence role
Molecular identity context
Supports
Reading product context beside a reviewed peptide identity.
Does not support
Automatic transfer of every product-level signal to peptide-level endpoint evidence.
Reference lineage
Evidence role
Reproducibility and source trace
Supports
Checking where labels, trials, safety reports, identity links, and curated measurements came from.
Does not support
A substitute for normalized evidence, context grouping, or endpoint review.
External source references
Evidence role
Original-source reading path
Supports
Reading the source reference in its native regulatory, registry, literature, or source context.
Does not support
Bypassing ADMETatlas curation status, interpretation boundaries, or endpoint-promotion policy.
Scientific interpretation limits
Endpoint interpretation
Requires compatible endpoint and context
Identity context
Reviewed identity context available
Causality and incidence
Not claimed from context counts
Reference lineage
Reference role map
Source families are separated by scientific role
Label, trial, safety, immune, identity-link, and PK evidence enter the product profile through different review paths. This module keeps their roles visible so users can trace evidence without over-reading context counts.
Source material
6
active reference families
Identity review
8
source-matching traces
Evidence lanes
57
PK plus context entries
Release view
public
current product profile
Reference role matrix
Source familyEvidence roleSupportsBoundaryRelated evidence
Label material
1 label · 0 sections
Evidence role
Regulatory product-label context
Supports
Label sections, label-derived PK statements, safety wording, route, formulation, and immunogenicity context when extracted.
Boundary
Label material supports product context. It becomes endpoint evidence only through the reviewed PK or endpoint extraction path.
Trial registry context
41 references
Evidence role
Human study-registration context
Supports
Trial identity, phase/status, intervention matching, and availability of results context around the product.
Boundary
Trial registry entries are study context unless endpoint-compatible results are extracted and reviewed separately.
Postmarketing reports
0 AE context entries
Evidence role
Safety surveillance context
Supports
Signal-aware reading of reported adverse-event context around marketed products.
Boundary
Report counts do not establish causality, incidence, or comparative product safety.
Immune and nonclinical context
1 entries
Evidence role
Assay and nonclinical support context
Supports
Immune-recognition assays, nonclinical safety context, and neighboring signals that help interpret the product profile.
Boundary
These entries are not clinical incidence or endpoint truth unless a review policy promotes a specific endpoint.
Product identity records
33 RxNorm identifiers
Evidence role
Named-product identity support
Supports
Matching named and dosed product presentations to a stable medication identity.
Boundary
Identity records do not provide an endpoint value, administration outcome, or route-specific clinical result.
Identity source traces
8 traces
Evidence role
Source-matching and identity-review context
Supports
Source records used to assess product-to-peptide identity relationships and retained audit context.
Boundary
Only an exact match to the current authoritative canonical identity supports a linked identity; all other traces remain product context.
Cited PK evidence
15 entries
Evidence role
Endpoint measurement trace
Supports
Rechecking source values, units, route, dose, matrix, population, and source context for PK summaries.
Boundary
PK entries remain context-bound measurements and should not be pooled across incompatible contexts.
Traceability note
Link references and selected label entries carry direct source links. Product-context entries may instead carry source labels and curated summaries in the structured profile. Both are provenance, but only direct reference fields should be displayed as citation links.
Data access & citation
Reproducible product view
The structured profile access reopens the same product view used by this page, including molecular identity, PK evidence, product context, and reference lineage for the current public release.
Current public release
ATL product ID
ATLPD0000051
public product profile
Linked peptides
1
identity link scope
PK evidence
15
cited measurement trace
Product-linked records
75
42 context · 33 identity support
References
9
label plus link traces
Analysis-ready access
Use the product profile access for product-specific reproducibility. Use full-release downloads for catalog-scale analysis, with the current source policy and data dictionary.
Structured product profile
Scope
Current product
Contents
Machine-readable profile for molecular identity, PK evidence summaries, product context, and reference lineage.
Boundary
Uses the public ATL product ID in the URL. Non-public product identifiers remain outside the navigation label.
Programmatic access
The request returns the structured product profile used by this page. It is the current product-specific reproducibility path while product-only tabular exports remain a release follow-up.
GET /api/v1/products/ATLPD0000051
curl -sS 'https://admetatlas.scbdd.com/api/v1/products/ATLPD0000051' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Use boundary
Use this module to reproduce the current product profile and locate full-release exports. Cross-product comparison still depends on compatible endpoint, species, route, dose, matrix, population, source, identity-link, and review context.